PRESS RELEASE

from Arix Bioscience PLC (isin : GB00BD045071)

Holding(s) in Company

Arix Bioscience PLC (ARIX)
Holding(s) in Company

17-Jul-2023 / 15:00 GMT/BST


TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BD045071

Issuer Name

ARIX BIOSCIENCE PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Ruffer LLP

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

14-Jul-2023

6. Date on which Issuer notified

17-Jul-2023

7. Total positions of person(s) subject to the notification obligation

.

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.977220

0.000000

4.977220

6440000

Position of previous notification (if applicable)

 

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BD045071

6440000

0

4.977220

0.000000

Sub Total 8.A

6440000

4.977220%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

 

 

 

 

Sub Total 8.B1

 

 

 

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

 

 

 

 

 

Sub Total 8.B2

 

 

 

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Ruffer LLP now controls the voting rights over 6,440,000 shares (less than 5% of the voting rights) of Arix Bioscience plc which are held by the discretionary clients of Ruffer LLP and its subsidiaries (the voting of which is all controlled by Ruffer LLP).
This change from 5% to less than 5% is due to the sale of 80,000 shares by Ruffer LLP on 14 July 2023.

12. Date of Completion

17-Jul-2023

13. Place Of Completion

Ruffer LLP



Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


ISIN:GB00BD045071
Category Code:HOL
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories:2.3. Major shareholding notifications
Sequence No.:258222
EQS News ID:1681769

 
End of AnnouncementEQS News Service

fncls.ssp?fn=show_t_gif&application_id=1681769&application_name=news&site_id=symex
See all Arix Bioscience PLC news